Randomized phase II feasibility study of mannitol or furosemide hydration in moderate dose of cisplatin-based chemotherapy with short hydration for advanced non-small cell lung cancer

INTERVENTION: to evaluate the proportion of renal toxicity in cisplatin‐based chemotherapy with short hydration using mannitol to evaluate the proportion of renal toxicity in cisplatin‐based chemotherapy with short hydration using furosemide CONDITION: advanced non small cell lung cancer PRIMARY OUTCOME: feasibility of mannnitol or furosemide forced diuresis of cisplatin‐based chemotherapy with short hydration INCLUSION CRITERIA: pathologically proven non small cell lung cancer stage IV or stage III without suitability for curative treatment or postoperative reccurent case combination chemotherapy using cisplatin plus 3rd generation anticancer drug at the age of 20 to 75 measurable tumor sites no prior chemotherapy no prior systemic anticancer therapy including palliative brain or bone irradiation within 1 week of proposed entry to this trial ECOG PS of 0 to 1 appropriate organ function acquisition of written informed consent